- Home
- AIMD
AIMD
Ainos Inc.
as 12-18-2024 4:00pm EST
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
| Founded: | 1984 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 6.0M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 132.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $4.29 | Next Earning Date: | 11-06-2024 |
| Revenue: | $40,633 | Revenue Growth: | -96.44% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Ainos Inc. News
AIMD Breaking Stock News: Dive into AIMD Ticker-Specific Updates for Smart Investing
ACCESSWIRE
6 hours ago
CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA
ACCESSWIRE
10 hours ago
Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA
ACCESSWIRE
5 days ago
Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement
ACCESSWIRE
14 days ago
Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing
Newsfile
16 days ago
Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug
ACCESSWIRE
a month ago
Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments
ACCESSWIRE
a month ago
Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025
Simply Wall St.
a month ago
Ainos Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.73 loss in 3Q 2023)
Compare AIMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AIMD Ainos Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.